567 related articles for article (PubMed ID: 17089011)
21. Correlations of TOP2A gene aberrations and expression of topoisomerase IIα protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry.
Meng H; Chen R; Li W; Xu L; Xu L
Pathol Int; 2012 Jun; 62(6):391-9. PubMed ID: 22612507
[TBL] [Abstract][Full Text] [Related]
22. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
[TBL] [Abstract][Full Text] [Related]
23. Solamargine enhances HER2 expression and increases the susceptibility of human lung cancer H661 and H69 cells to trastuzumab and epirubicin.
Liang CH; Shiu LY; Chang LC; Sheu HM; Tsai EM; Kuo KW
Chem Res Toxicol; 2008 Feb; 21(2):393-9. PubMed ID: 18078328
[TBL] [Abstract][Full Text] [Related]
24. Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1.
Furuta E; Pai SK; Zhan R; Bandyopadhyay S; Watabe M; Mo YY; Hirota S; Hosobe S; Tsukada T; Miura K; Kamada S; Saito K; Iiizumi M; Liu W; Ericsson J; Watabe K
Cancer Res; 2008 Feb; 68(4):1003-11. PubMed ID: 18281474
[TBL] [Abstract][Full Text] [Related]
25. Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression.
Menendez JA; Ropero S; Lupu R; Colomer R
Oncol Rep; 2004 Jun; 11(6):1241-52. PubMed ID: 15138562
[TBL] [Abstract][Full Text] [Related]
26. Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?
Menendez JA; Colomer R; Lupu R
Med Hypotheses; 2005; 64(2):342-9. PubMed ID: 15607569
[TBL] [Abstract][Full Text] [Related]
27. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.
Tanner M; Järvinen P; Isola J
Cancer Res; 2001 Jul; 61(14):5345-8. PubMed ID: 11454672
[TBL] [Abstract][Full Text] [Related]
28. Effect of gamma-linolenic acid on the transcriptional activity of the Her-2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Colomer R; Lupu R
J Natl Cancer Inst; 2005 Nov; 97(21):1611-5. PubMed ID: 16264182
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells.
Menendez JA; Oza BP; Atlas E; Verma VA; Mehmi I; Lupu R
Oncogene; 2004 Jun; 23(28):4945-58. PubMed ID: 15094777
[TBL] [Abstract][Full Text] [Related]
30. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
31. Functional antagonism between inhibitor of DNA binding (Id) and adipocyte determination and differentiation factor 1/sterol regulatory element-binding protein-1c (ADD1/SREBP-1c) trans-factors for the regulation of fatty acid synthase promoter in adipocytes.
Moldes M; Boizard M; Liepvre XL; Fève B; Dugail I; Pairault J
Biochem J; 1999 Dec; 344 Pt 3(Pt 3):873-80. PubMed ID: 10585876
[TBL] [Abstract][Full Text] [Related]
32. Sterol regulatory element-binding protein-1 participates in the regulation of fatty acid synthase expression in colorectal neoplasia.
Li JN; Mahmoud MA; Han WF; Ripple M; Pizer ES
Exp Cell Res; 2000 Nov; 261(1):159-65. PubMed ID: 11082286
[TBL] [Abstract][Full Text] [Related]
33. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
[TBL] [Abstract][Full Text] [Related]
34. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
[TBL] [Abstract][Full Text] [Related]
35. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
36. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.
Järvinen TA; Tanner M; Rantanen V; Bärlund M; Borg A; Grénman S; Isola J
Am J Pathol; 2000 Mar; 156(3):839-47. PubMed ID: 10702400
[TBL] [Abstract][Full Text] [Related]
37. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
38. Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway.
Swinnen JV; Heemers H; Deboel L; Foufelle F; Heyns W; Verhoeven G
Oncogene; 2000 Oct; 19(45):5173-81. PubMed ID: 11064454
[TBL] [Abstract][Full Text] [Related]
39. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
40. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.
Wang J; Xu B; Yuan P; Zhang P; Li Q; Ma F; Fan Y
Breast Cancer Res Treat; 2012 Sep; 135(2):531-7. PubMed ID: 22864769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
